Shots:
- SteinCares has entered into a strategic licensing agreement with Shilpa Medicare to commercialize a biosimilar across Latin America (LATAM)
- As per the deal, SteinCares secures exclusive rights to register, commercialize, & distribute the biosimilar across the region, while SBPL will finalize development & undertake commercial manufacturing at its Dharwad, India facility
- Partnership combines SBPL’s biologics development & high-quality commercial manufacturing capabilities with SteinCares’ integrated regional platform, accelerating market access, & expanding the reach of advanced biologics across key LATAM markets
Ref: PRnewswire | Image: SteinCares & Shilpa | Press Release
Related News: Bio-Thera Solutions and SteinCares Broaden Collaboration to Commercialize (Biosimilar, Dupilumab) in Latin America
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
